244
Participants
Start Date
December 16, 2020
Primary Completion Date
March 31, 2030
Study Completion Date
March 31, 2031
TAS0953/HM06
Phase 1: oral, starting dose 20mg twice a day, until recommended phase 2 dose, continuous daily dosing, cycles lasting 21 days
TAS0953/HM06
Phase 2: oral, recommended dose twice a day, continuous daily dosing, cycles lasting 21 days
TERMINATED
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health, New York
TERMINATED
Memorial Sloan Kettering Cancer Center, New York
TERMINATED
The Sarah Cannon Research Institute/Tennessee Oncology, Nashville
TERMINATED
Henry Ford Hospital, Detroit
TERMINATED
START Midwest - Cancer & Hematology Centers of Western Michigan, Grand Rapids
TERMINATED
Chao Family Comprehensive Cancer Center, Orange
TERMINATED
Stanford Cancer Center, Stanford
TERMINATED
Massachusetts General Hospital, Boston
TERMINATED
The University of Texas M. D. Anderson Cancer Center, Houston
RECRUITING
National Cancer Center Hospital East, Kashiwa-shi
RECRUITING
Tohoku University Hospital, Sendai
RECRUITING
Okayama University Hospital, Okayama
RECRUITING
Kansai Medical University Hospital, Hirakata-shi
RECRUITING
Osaka International Cancer Institute, Osaka
RECRUITING
Shizuoka Cancer Center, Shunto-gun
RECRUITING
National Cancer Center Hospital, Chuo-ku
RECRUITING
The Cancer Institute Hospital of JFCR, Koto-ku
Taiho Pharmaceutical Co., Ltd.
INDUSTRY